Semaglutide supplies return to Australia ahead of schedule Limited quantities of the medication will be available from late next week, the TGA has said, but GPs have been asked to not prescribe it off-label.
Study reveals global burden of early T2DM The number of young people with type 2 diabetes has risen substantially in the past 30 years, research involving more than 200 countries shows.
In Practice: Diabetes management with current drug shortages An upcoming webinar will address ongoing diabetes medication shortages and aim to help GPs safely negotiate therapies.
TGA threatens illegal semaglutide promoters with jail, $1m fines Advertisers and social media influencers have been warned against publicly spruiking the drug for the purposes of weight loss.
Semaglutide unavailable in Australia until April 2023 GPs have been told not to initiate any new patients on either semaglutide or dulaglutide, which will also only have ‘limited availability’.
Diabetes medication shortage worsens There is not expected be enough dulaglutide in Australia to fill all prescriptions for type 2 diabetes patients until at least early 2023, the TGA has warned.
Practical tool aims to help GPs manage obesity Two decades’ worth of evidence has been collated into an algorithm GPs can use when managing patients with obesity.
Shortage of diabetes drug flagged until 2023 While semaglutide supply will be intermittent, its current availability should be ‘enough for approved use’, the manufacturer has advised.
‘Nonsensical’ to stop GPs approving access to glucose monitors The decision to block GPs from certifying patient access to the devices ‘needs to be reviewed and rectified,’ the RACGP president says.
CVD and diabetes rates spike post-COVID: Study The risk of contracting diabetes is especially high in the first four weeks after infection, but returns to baseline within months.